Apollomics, Inc. Share Price & Technical Analysis
APLM · $14.09 (-1.54%)
Healthcare / Biotechnology
$14.09
-1.54%
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung …
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
6% return in May, -21% avg return in past 3 year May month.
-28% return in 2026, 21% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -12% | 12% | -20% | -14% | 6% | – | – | – | – | – | – | – | -28% |
| 25 | -15% | -28% | -3% | 2% | 2% | 6% | -9% | -33% | 372% | -24% | 0% | 24% | 293% |
| 24 | -17% | -9% | 0% | -38% | -31% | -30% | -10% | -38% | 18% | -16% | -25% | 7% | -189% |
| 23 | 1% | 1% | 130% | -78% | -35% | 34% | -9% | -6% | -21% | -78% | 16% | 5% | -41% |
| 22 | 0% | 0% | 0% | 1% | 0% | 0% | 0% | 0% | 0% | 1% | 1% | 1% | 5% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$31.54M
P/E ratio
—
52W high
$42.12
52W low
$3.66
Volume
7,611
Beta
1.52
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Apollomics, Inc. share price today?
- Apollomics, Inc. (APLM) last traded around $14.09 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does APLM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for APLM. Download the app for real-time alerts.
- How can I analyze Apollomics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.